Maprotiline (Ludiomil)

What it treats

Maprotiline is approved by the U.S. Food and Drug Administration to treat depression, including depression accompanied by anxiety.

Off-label use is rare today. Off-label means a purpose the label doesn't formally list even though evidence and practice support it.

How it works

Maprotiline acts almost purely on norepinephrine, one of the brain's chemical messengers involved in alertness, energy, and mood. It also blocks histamine and, to a lesser extent, acetylcholine, which is why sedation and mild anticholinergic side effects are common.

As with other antidepressants, the effect isn't from the first dose. It comes from slower changes in the brain over the following weeks.

Receptor mechanism (detail)

Maprotiline is a tetracyclic antidepressant and a strong norepinephrine transporter (NET) inhibitor, with essentially no SERT activity. It has moderate H1 and muscarinic blockade. The tetracyclic ring structure is thought to contribute to its higher seizure risk compared with tricyclics, especially at doses above 200 mg per day or with rapid titration.

Potency and typical dosing pattern

Ranges are typical framework only, not a prescription for any individual.

Starting is 25 to 75 mg at bedtime. Usual range is 100 to 150 mg per day; the manufacturer historically capped daily dose at 225 mg because of seizure risk. Slow titration (2 weeks between meaningful dose changes) reduces seizure risk.

Safety monitoring

• Seizure risk. Higher than for other antidepressants in this class, especially above 200 mg per day.
• ECG at baseline, and periodically at higher doses. Tricyclics prolong QRS, PR, and QTc.
• Overdose is dangerous. Narrow therapeutic index; even modest overdoses can cause fatal arrhythmias and seizures.
• Anticholinergic burden.
• Orthostatic vitals.
• Suicidality in the first 4 weeks, especially under age 25 (FDA boxed warning).
• Serotonin syndrome, avoid MAOIs.
• Reassess at 2, 4, and 6 to 8 weeks.

What to expect

Common side effects

Common side effects include:

• Drowsiness.
• Dry mouth.
• Constipation.
• Blurred vision.
• Dizziness on standing.
• Weight gain.
• Skin rash (more common than with tricyclics).

If a side effect is severe, or it isn't improving, that's a conversation to have with the prescriber rather than a reason to stop on your own.

Serious side effects and warnings

Serious problems are uncommon, but a few are worth knowing.

Boxed warning. Like all antidepressants, maprotiline carries an FDA boxed warning that it can increase suicidal thoughts and behaviors in children, teenagers, and young adults under 25, especially in the first weeks of treatment or after a dose change.

• Seizures. Maprotiline's seizure risk is higher than for other tricyclics, especially at doses above 200 mg per day or with rapid titration. Concomitant use of other seizure-lowering drugs raises the risk further.
• Effects on heart rhythm. ECG monitoring matters.
• Danger in overdose. Fatal arrhythmias and seizures are both risks.
• Skin reactions. Rash can be more common than with tricyclics; a spreading or blistering rash needs urgent attention.
• Serotonin syndrome. Do not combine with MAOIs.
• A drop in blood pressure on standing.

Sexual side effects

Maprotiline can reduce sex drive and make orgasm or erection more difficult. Rates are similar to other tricyclics. If sexual side effects appear, they're worth raising with the prescriber.

Weight, appetite, and sleep

Maprotiline commonly increases appetite and causes weight gain. It's sedating, so it's often dosed at bedtime.

Starting and dosing basics

This section is general background, not a dosing instruction for any individual. The right dose is a decision for a prescriber.

Maprotiline comes as tablets. Starting doses are low, and titration is deliberately slow (2 weeks between meaningful changes) because rapid titration raises seizure risk. A prescriber caps the dose based on tolerability and seizure considerations.

Missed doses and interactions

If you miss a dose, take it when you remember, unless it's almost time for the next dose. Skip the missed dose and carry on. Don't take two doses to make up for one.

Interactions matter. Maprotiline must not be combined with MAOI antidepressants, and a gap is needed when switching. Alcohol and other CNS depressants add to sedation. Bupropion, tramadol, and other seizure-lowering drugs stack the seizure risk. Give every prescriber and pharmacist a full list of your medications and supplements, including over-the-counter ones.

Stopping and tapering

Maprotiline isn't a controlled substance and isn't habit-forming in the usual sense.

The body does adjust to it, and stopping abruptly can cause discontinuation symptoms: nausea, sweating, sleep disturbance, and low mood. A gradual taper planned with a prescriber avoids most of this.

Pregnancy and breastfeeding

This is an area where individual circumstances matter and the decision belongs with a clinician. Untreated depression carries its own risks during pregnancy, and maprotiline passes into breast milk. Anyone who is pregnant, planning a pregnancy, or breastfeeding should talk it through with their prescriber so the specific risks and benefits can be weighed for their situation.

Cost and generic availability

Maprotiline is available as a generic. It isn't widely stocked because it isn't commonly prescribed, so a pharmacy may need time to source it.

Common questions

Why is the seizure risk higher with maprotiline? The tetracyclic ring structure seems to contribute. Risk rises above 200 mg per day, with rapid titration, and with other seizure-lowering drugs. That's why slow titration and a modest maximum dose matter.

Is it still used? Rarely. The seizure risk plus the availability of newer antidepressants make it a hard sell today.

Is it dangerous in overdose? Yes. Both arrhythmias and seizures are recognized features of maprotiline overdose.

Will it cause weight gain? It often does. If weight gain becomes a concern, raise it with your prescriber.

Is it addictive? No. It's not a controlled substance and doesn't cause cravings. Stopping should still be done gradually.

Questions to ask your prescriber

• Given the seizure risk, why maprotiline over other options?
• How slow will we titrate, and what's the maximum dose we're aiming for?
• Which side effects should I call about right away?
• Do we need an ECG at baseline?
• If we decide to stop it later, how would we do that safely?

Sources

This guide draws on current prescribing information and public health references and current as of June 8, 2026. It is reviewed for clinical accuracy and updated as guidance changes.

• U.S. Food and Drug Administration. Maprotiline hydrochloride (Ludiomil) prescribing information.
• MedlinePlus, U.S. National Library of Medicine. Maprotiline.
• National Institute of Mental Health. Mental health medications.
• American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder.
• American Geriatrics Society. Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (2023).